wxk001

Walter K. Kraft, MD

Contact Dr. Kraft

132 South Tenth Street
1170 Main Building
Philadelphia, PA 19107

(215) 955-9077
(215) 955-5681 fax

Most Recent Peer-reviewed Publications

  1. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
  2. Stability-indicating lc-ms method for determination of stability of extemporaneously compounded buprenorphine oral syringes for neonatal abstinence syndrome
  3. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers
  4. Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy
  5. Development of an abbreviated symptom score for the neonatal abstinence syndrome
  6. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
  7. Simultaneous quantitative LC–MS method of ketamine, midazolam and their metabolites (dehydronorketamine, norketamine and 1hydroxymidazolam) for its application in patients on extracorporeal membrane oxygenation (ECMO) therapy
  8. Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome?
  9. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil
  10. Pharmacokinetics of vaginal progesterone in pregnancy
  11. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy
  12. Could Postnatal Age–Related Uridine Diphosphate Glucuronic Acid Be a Rate-Limiting Factor in the Metabolism of Morphine During the First Week of Life?
  13. Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome
  14. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects
  15. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
  16. Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS)
  17. Incorporation of Quality and Safety Principles in Maintenance of Certification: A Qualitative Analysis of American Board of Medical Specialties Member Boards
  18. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration
  19. Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects (Clinical Drug Investigation, (2019), 10.1007/s40261-019-00764-x)
  20. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling
  21. Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers
  22. The Impact of a Transition of Care Program on Acute Myocardial Infarction Readmission Rates
  23. Subdermal ultrasound contrast agent injection for sentinel lymph node identification: An analysis of safety and contrast agent dose in healthy volunteers
  24. The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome
  25. Buprenorphine in Neonatal Abstinence Syndrome